Steffen Walter
Fortuna: 115 100 $ al 31/05/2026
Fortuna: 115 100 $ al 31/05/2026
Steffen Walter is the founder of Immatics US, Inc., founded in 2015, holding the title of Chief Scientific Officer since 2015.
Dr. Walter currently holds the position of Chief Operations Officer at Immatics Biotechnologies GmbH since 2023, with the job starting in 2005 and ongoing.
Dr. Walter also holds the position of Chief Operations Officer at Immatics NV since 2023, with the job starting in 2020 and ongoing.
Dr. Walter completed a doctorate degree at Eberhard Karls Universität Tübingen.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
IMMATICS N.V. 0,01 % | 18/03/2026 | 10.000 ( 0,01 % ) | 115 100 $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| IMMATICS N.V. | Director de Operaciones | 21/03/2023 |
Immatics US, Inc.
Immatics US, Inc. BiotechnologyHealth Technology Develops adoptive cell therapies for treatment of cancer | Fundador | 01/01/2015 |
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH BiotechnologyHealth Technology Operates as a bio technology company that develops and delivers T cell redirecting immunotherapies for treatment of cancer | Director de Operaciones | 21/03/2023 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH BiotechnologyHealth Technology Operates as a bio technology company that develops and delivers T cell redirecting immunotherapies for treatment of cancer | Health Technology |
Eberhard Karls Universität Tübingen
Eberhard Karls Universität Tübingen Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Immatics US, Inc.
Immatics US, Inc. BiotechnologyHealth Technology Develops adoptive cell therapies for treatment of cancer | Health Technology |
Immatics NV
Immatics NV Pharmaceuticals: MajorHealth Technology Engages in developing immunotherapies for cancer treatments | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.